The biggest workplace concern for interventional cardiologists and cath lab staff is their daily exposure to ionizing ...
Abbott today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation guided by optical coherence tomography (OCT) compared to angiography. The trial (ILUMIEN IV) is the first large-scale randomized global study using Abbott's OCT imaging in patients with high-risk, complex coronary artery disease. Patients in the study will be randomized to either OCT-guided or traditional angiography to guide placement of one or more Xience everolimus-eluting coronary stents.
https://www.dicardiology.com/channel/vascular-closure-devicesCardiva Medical announced the company received U.S. Food and Drug Administration (FDA) approval for an expanded indication of the Vascade Vascular Closure System. Already approved for use in arterial closure, Vascade is now FDA-approved for use in 5-7F femoral venous closures as well. This expansion creates an opportunity to better treat patients undergoing interventional cardiac catheterization procedures, while also greatly increasing the available market for the device.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
University Hospitals Harrington Heart & Vascular Institute has officially opened the APOLLO trial, implanting the first Intrepid transcatheter mitral valve replacement system in the study. Alan Markowitz, M.D., and Guilherme F. Attizzani, M.D., performed the procedure, the first in the state of Ohio.
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint with a statistically significant reduction in all-cause mortality plus frequency of cardiovascular-related hospitalizations compared to placebo at 30 months. The preliminary safety data showed that tafamidis was generally well tolerated in this population and no new safety signals were identified.1
YMCA of the USA (Y-USA) and the American Heart Association (AHA) are combining efforts to help more people better manage their blood pressure. Beginning this spring, more than 100 clinics participating in the Target: BP initiative will be able to refer qualified patients to enroll at no cost in the YMCA’s Blood Pressure Self-Monitoring program.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
April 5, 2018 — Medical imaging company Brainomix has attracted £7m ($9.8 million) of investment to bring its artificial ...
April 5, 2018 — Diagnostic and Interventional Cardiology (DAIC) magazine received the 2018 Jesse H. Neal Award for Best ...
The Ohio State University Wexner Medical Center will establish the nation’s first center dedicated to treating those with heart failure and arrhythmia with gifts totaling $18 million from Bob and Corrine Frick.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Boston Scientific Corp. announced the acquisition of Securus Medical Group Inc., a privately-held company that has developed a thermal monitoring system for the continuous measurement of esophageal temperature. Boston Scientific has been an investor in Securus since 2016, and the transaction price for the remaining stake not already owned consists of $40 million in cash up-front, as well as up to $10 million in contingent payments based on regulatory achievements and commercial milestones.
April 4, 2018 — The U.S. Food and Drug Administration (FDA) has cleared the Somatom Edge Plus computed tomography (CT) ...
April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
GE Healthcare announced the sale of its Value-Based Care Division — including its software assets for Enterprise Financial Management, Ambulatory Care Management and Workforce Management — to private equity investment firm Veritas Capital. The sale, expected to be completed in third quarter 2018, was valued at $1.05 billion in cash.
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magazine ...
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella CP heart pump with SmartAssist, utilizing an optical sensor. The company said these advances in technology and software are designed to improve productivity, ease of use and patient management to ensure optimal patient care.